ORPHA:216796
Osteogenesis imperfecta type 1
Also known as: Non-deforming osteogenesis imperfecta · OI type 1 · Van der Hoeve syndrome · Adair-Dighton syndrome · Mild osteogenesis imperfecta
Publications
1,497
Trials
2
Interventional, condition-specific
Researchers
1,122
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A mild form of osteogenesis imperfecta (OI) characterized by increased bone fragility and low bone mass that clinically manifests with increased susceptibility to bone fractures (including vertebral crush fractures), normal height or short stature (typically between 0 and -2.0 SD scores), mild (Cobb angle <30 degrees) or no scoliosis, blue sclera, and in dentinogenesis imperfecta, and mild long bone bowing bone deformities.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008146
- OMIM:166200
- UMLS:C0023931
- NCIT:C99003
Additional Mondo synonyms (6)
COL1A1-related osteogenesis imperfecta · OI1 · mild osteogenesis imperfecta · non-deforming osteogenesis imperfecta · osteogenesis imperfecta type 1 · osteogenesis imperfecta type I
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,497 matched papers (827 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
2 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,497
1,497 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,497 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
827 in the last 10 years · low confidence
Phrase hits: 1,497 · MeSH hits: 0
Who's working on it?
1,122
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Rauch F9 papers · 2023
Shriners Hospital for Children, 1529 Cedar Avenue, Montréal, Québec H3G 1A6, Canada; Department of Pediatrics, McGill University, 1529 Cedar Avenue, Montréal, Québec H3G 1A6, Canada; Centre de Réadaptation Marie-Enfant, Research Center, Hôpital Sainte-Justine, 5200 Bélanger Street East, Montréal, Québec H1T 1C9, Canada.
Papers in Europe PMC - 02Liu Y7 papers · 2025
Jiangxi Maternal and Child Health Hospital, Nanchang, China.
Papers in Europe PMC - 03Glorieux FH6 papers · 2023
Shriners Hospital for Children, 1529 Cedar Avenue, Montréal, Québec H3G 1A6, Canada; Department of Pediatrics, McGill University, 1529 Cedar Avenue, Montréal, Québec H3G 1A6, Canada.
Papers in Europe PMC - 04Jakubowska-Pietkiewicz E5 papers · 2025
Department of Pediatrics, Newborn Pathology and Bone Metabolic Diseases, Medical University of Lodz, Lodz, Poland.
Papers in Europe PMC - 05Chen S4 papers · 2025
The Second Affiliated Hospital of Guangxi Medical University, Nanning, 530000, Guangxi, China.
Papers in Europe PMC - 06Chen Y4 papers · 2026
Prenatal Diagnosis Center of the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Papers in Europe PMC - 07Eekhoff EMW4 papers · 2026
Rare Bone Disease Center Amsterdam, 1081 HV Amsterdam, The Netherlands.
Papers in Europe PMC - 08Liu L4 papers · 2022
Department of Orthopedic Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.
Papers in Europe PMC - 09Micha D4 papers · 2026
Department of Human Genetics, Amsterdam Reproduction and Development, Amsterdam Movement Sciences, Amsterdam UMC, Amsterdam, The Netherlands.
Papers in Europe PMC - 10van Dijk FS4 papers · 2024
North West Thames Regional Genetics Service, London North West University Health Care NHS Trust, Harrow, UK.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 58 trials are registered for osteogenesis imperfecta, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
2 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 82.4th percentile).
low confidence · 82.4th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07478224·RECRUITING·An Interventional Study to Evaluate the Impact of Blood Flow Restriction Training on Muscle, Bone, and Quality of Life in Adults With Osteogenesis Imperfecta Type I
Conditions: Osteogenesis Imperfecta, Type I·Matched via name phrase
Broader category: osteogenesis imperfecta
58
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07666269·NOT YET RECRUITING·Morphology in Oral Rare Syndromes & Artificial Intelligence for Clinical Diagnosis
Conditions: Osteogenesis Imperfecta · Rare Bone Disorders · Hypophosphatemia · X-Linked·Matched via name phrase
- NCT07366086·RECRUITING·Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
Conditions: Osteogenesis Imperfecta·Matched via name phrase
- NCT05559801·NOT YET RECRUITING·Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
Conditions: Osteogenesis Imperfecta · Osteogenesis Imperfecta Type III·Matched via name phrase
- NCT07412782·RECRUITING·REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)
Conditions: Osteogenesis Imperfecta · Osteoporosis · Hypogonadisms · Neoplasia·Matched via name phrase
- NCT05927389·RECRUITING·Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis Imperfecta
Conditions: Osteogenesis Imperfecta·Matched via name phrase
- NCT07062588·RECRUITING·Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
Conditions: Osteogenesis Imperfecta (OI)·Matched via name phrase
- NCT04152551·RECRUITING·Effects of Bisphosphonates on OI-Related Hearing Loss
Conditions: Osteogenesis Imperfecta·Matched via name phrase
- NCT07557446·RECRUITING·A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
Conditions: Osteogenesis Imperfecta (OI)·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26Likely covered — the policy lists Osteogenesis imperfecta as a category (Group 2), and this condition is a form of it. Confirm eligibility with a Centre of Excellence.
Group 2 — long-term / lifelong lower-cost interventions
NPRD envisages State Government support for dietary formulae, hormones, and other lower-cost interventions. This is a different route from the central CoE ₹50 lakh pathway; ask your state health department and a CoE which channel applies.
Central CoE funding may also apply depending on current rules — confirm with a notified Centre of Excellence. Do not assume the ₹50 lakh ceiling covers Group 2 by default. Verify
Centres of Excellence (15)
- All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
- Maulana Azad Medical College — New Delhi, Delhi
- Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
- Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
- Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
- King Edward Memorial Hospital — Mumbai, Maharashtra
- Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
- Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
- Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
- All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
- Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
- All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
- Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
- All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
- Assam Medical College & Hospital — Dibrugarh, Assam
Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Osteogenesis imperfecta type 1" OR "Non-deforming osteogenesis imperfecta" OR "OI type 1" OR "Van der Hoeve syndrome" OR "Adair-Dighton syndrome" OR "Mild osteogenesis imperfecta" OR "COL1A1-related osteogenesis imperfecta" OR "osteogenesis imperfecta type I"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Osteogenesis imperfecta type 1" OR "Non-deforming osteogenesis imperfecta" OR "OI type 1" OR "Van der Hoeve syndrome" OR "Adair-Dighton syndrome" OR "Mild osteogenesis imperfecta" OR "COL1A1-related osteogenesis imperfecta" OR "osteogenesis imperfecta type I"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"osteogenesis imperfecta"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: OI1
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (1497) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T09:41:52.419Z
